Press Room

News / Jun 30, 2022

Hovione receives an honorable mention at the “Innovation in Ecosystem 2022” competition

COTEC Innovation Summit

Mencao Honrosa COTEC Innovation Summit 2022 Hovione

On June 29th, at the COTEC Innovation Summit, Hovione’s case study, presented in partnership with WeADD, received an honorable mention at the “Innovation in Ecosystem” 2022 competition. The ceremony took place at the Aveiro Congress Center, and João Ventura, Business Director Inhalation Solutions, represented our company.

Hovione was a finalist following a presentation provided together with WeADD, during the COTEC Xperience 4.0 sessions, as part of a collaboration that supports the development of the product “8Shot Dry Powder Inhaler (DPI)”.

COTEC Portugal is a multisectoral business association that promoted four central axes in this edition of the COTEC Innovation Summit: Industrialization, Sustainability, Knowledge and Competitiveness.

 

Learn more about our Devices

 

joao ventura receives honorable mention from COTEC Innovation Award | Hovione
From left to right: João Ventura (Hovione), Sónia Josué (WeAdd), Adriano Fidalgo (Astrolábio)

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026